GAOMA Therapeutics
Laurent Bezin has extensive work experience in the field of neuroscience research and epilepsy. Laurent currently serves as the Deputy Director at the Lyon Neuroscience Research Center since December 2019. Additionally, they are a Co-founder of GAOMA Therapeutics since February 2019. Prior to this, Laurent was the Deputy Director at the Epilepsy Institute from January 2016. Laurent has also held the position of Co-team leader at TIGER: Translational & Integrative Group in Epilepsy Research since January 2011.
Laurent Bezin's education history began with their completion of a Baccalauréat at Collège et Lycée de la Croix Blanche from 1978 to 1986. Laurent then pursued a Maîtrise in Physiologie mention Pharmacologie at Université des Sciences et Techniques du Languedoc, Montpellier 2, France from 1986 to 1990. Following this, they obtained a DEA in Neurosciences from Université Claude Bernard Lyon 1 in 1990-1991. Finally, Laurent completed their education with a Thèse de Doctorat in Neurosciences from the same institution, Université Claude Bernard Lyon 1, from 1991 to 1995.
This person is not in any teams
GAOMA Therapeutics
GAOMA Therapeutics is a biotech company specialized in the development of lipids derivatives as innovative therapeutic molecules. Lipids are a class of compounds that has been largely under-exploited, whereas it plays a key role in many medical conditions. GAOMA has the ambition to tap into the therapeutic potential of lipids. The company’s first drug candidate, GAO-3-02, is a novel patented active ingredient. It aims to address epilepsy and cognitive disorders, by targeting neuroinflammation and brain plasticity. In various preclinical experiments, GAO-3-02 has thus demonstrated its ability to limit seizures, protect and restore cognitive functions, on the long term, and with a good tolerance. With 50 to 70 million people affected in the world, epilepsy is one of the most common severe neurological conditions. The disease triggers seizures in patients, a phenomenon well known to the general public, but also various other disorders, such as cognitive impairment. Existing anti-epileptic drugs have relatively similar mechanisms of action, with the direct objective to disable neuronal activity. These drugs unfortunately leave a high unmet medical need: they are symptomatic treatments addressing seizures only, with a limited efficacy (one third of patients is drug resistant), and with poor tolerance (side effects among a majority of patients).